February 13, 2015 – IGPA has filed its inaugural submission with the Office of the United States Trade Representative (USTR) as part of USTR`s 2015 Special 301 Review. The IGPA submission identifies a number of trade barriers and impediments for the generic pharmaceutical and biosimilar medicines industries.
